Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
Net loss: US$25.6m (loss widened by 23% from 2Q 2023). US$0.24 loss per share (further deteriorated from US$0.23 loss in 2Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Tango Therapeutics Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 160%. Earnings per share (EPS) also surpassed analyst estimates by 27%. Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 5.7% from a week ago. Risk Analysis You still need to take note of risks, for example - Tango Therapeutics has 3 warning signs (and 1 which is potentially serious) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article b
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data [Seeking Alpha]Seeking Alpha
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Tango Therapeutics to Participate in Upcoming Investor ConferencesBusiness Wire
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at Wedbush from $11.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
TNGX
Earnings
- 8/7/24 - Beat
TNGX
Sec Filings
- 9/17/24 - Form 4
- 9/13/24 - Form 144
- 9/9/24 - Form 4
- TNGX's page on the SEC website